Tempest Therapeutics (NASDAQ:TPST) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Tempest Therapeutics (NASDAQ:TPST) announced its quarterly earnings data on Friday. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.11, Zacks reports.

Tempest Therapeutics Stock Performance

Shares of TPST stock traded down $0.00 on Friday, reaching $0.38. The stock had a trading volume of 153,039 shares, compared to its average volume of 881,778. The stock has a market cap of $7.64 million, a P/E ratio of -0.09 and a beta of -1.54. The company has a 50 day simple moving average of $0.70 and a 200 day simple moving average of $1.40. Tempest Therapeutics has a 1 year low of $0.34 and a 1 year high of $9.75.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TPST shares. Wall Street Zen upgraded shares of Tempest Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Friday, October 9th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

About Tempest Therapeutics

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s approach is designed to address both tumor cells and the immune environment surrounding them, with the goal of stimulating antitumor immune responses and improving the effectiveness of cancer treatment. Tempest’s pipeline includes TPST-1120, an orally administered, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα). The company has evaluated TPST-1120 in clinical studies involving advanced solid tumors, including hepatocellular carcinoma, and has investigated its use in combination with other cancer therapies.